Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    AMP945

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Adagene Presents Data on Anti-CTLA-4 SAFEbody® ADG126 at SITC
    Adagene Presents Data on Anti-CTLA-4 SAFEbody® ADG126 at SITC

    07 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/07/2976860/0/en/Adagene-Presents-Two-Posters-with-New-Insights-on-Increased-Therapeutic-Index-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-Muzastotug-and-Data-Reinforcing-Clinical-Safety-and-Efficacy-fo.html

    GLOBENEWSWIRE
    07 Nov 2024
    Share Share
    Adagene Presents Results Reinforcing Best-in-Class Profile of ADG126
    Adagene Presents Results Reinforcing Best-in-Class Profile of ADG126

    16 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/16/2810362/0/en/Adagene-Presents-Interim-Results-Reinforcing-Best-in-Class-Profile-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-Metastatic-Microsatellite-s.html

    GLOBENEWSWIRE
    16 Jan 2024
    Share Share
    Adagene To Present Results of anti-CTLA-4 SAFEbody ADG126 with Pembrolizumab
    Adagene To Present Results of anti-CTLA-4 SAFEbody ADG126 with Pembrolizumab

    04 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/04/2803770/0/en/Adagene-To-Present-Interim-Results-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-MSS-CRC-at-ASCO-GI-Symposium.html

    GLOBENEWSWIRE
    04 Jan 2024
    Share Share